Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metopon is a semisynthetic opioid analgesic, also known chemically as methyldihydromorphinone. It is a derivative of morphinan, structurally related to morphine and hydromorphone, and acts primarily as an agonist at the mu-opioid receptor. Like other opioids, it exhibits potent analgesic (pain-relieving) properties and is classified as a narcotic analgesic. Developed in the 20th century, it was investigated for pain management; its clinical use is limited and it is classified as a controlled substance due to its potential for abuse and dependence[2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metopon.